Cervical Cytologic Smear False Negative Fraction

Wang, Scott E.; Ritchie, M.J.; Atkinson, Barbara

doi:10.1159/000333169

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such a relationship has been previously described. 14 The disagreement rates reported in other studies vary through a wide range. Tabbara and Sidawy 1 found a 0.18% disagreement rate when reviewing 2,124 Pap smears.…”

Section: Discussionmentioning

confidence: 96%

Quality assurance in cervical screening of a high risk population: A study of 65,753 reviewed cases in Parana screening program, Brazil

et al. 2005

View full text Add to dashboard Cite

Epidemiological data from the Quality Assurance Unit (QAU) of the Cervical Cancer Screening Program of Paraná is discussed. Slides (65,753) reviewed by the QAU, from October 1997 to July 1999, were analyzed. Relations between agreement rate, diagnostic categories, and age groups were tested. The overall agreement rate was 97.04% (kappa +/- 95%, confidence interval = 0.888 +/- 0.003). Low-grade squamous intraepithelial lesion (LSIL) showed its peak prevalence in patients < or = 19 yr (8.3%). High-grade squamous intraepithelial lesion (HSIL) was more common in women between 40 and 49 yr (5.0%). Squamous-cell carcinoma (SCC) was almost exclusively seen in women > or = 40 yr. The lowest agreement rates were seen in adenocarcinoma (54.5%; kappa = 0.667) and LSIL cases (76.3%, kappa = 0.822), and in women < or = 19 yr (95.8%). It was concluded that constant monitoring to assess specific errors allows directed measures. The 10% rescreening model of quality assurance proved to be effective in a low resources setting with a positive overall financial impact.

show abstract

Section: Discussionmentioning

confidence: 96%

Quality assurance in cervical screening of a high risk population: A study of 65,753 reviewed cases in Parana screening program, Brazil

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Inwieweit diese Falsch-negativ-Rate zulasten der Abstrichentnahme oder der -befundung geht, war nicht Gegenstand dieser Analyse. In einer Untersuchung zur Sensitivität der Zytologie wurde konstatiert, dass eine Falsch-negativ-Rate von 5 % (Anteil falsch-negativer Abstriche im Verhältnis zu allen richtig-positiven plus falsch-negativen Abstrichen) auch bei großen Anstrengungen der Zytologieassistenten und Zytologen nur über einen kurzen Zeitraum zu halten ist [13]. Bei einer Reevaluation von Zervixabstrichen in Österreich wurde hochgerechnet, dass bei Zervixkarzinomen zwischen 0,009 und 0,018 % aller untersuchten Abstriche falsch-negativ befundet werden [9].…”

Section: Falsch-negative Screeningergebnisseunclassified

Zervixkarzinome in Mecklenburg-Vorpommern

Marquardt¹,

Stubbe²,

Broschewitz³

2015

Pathologe

View full text Add to dashboard Cite

show abstract

Reevaluation von Zervixabstrichen bei Zervixkarzinompatientinnen

Regitnig

Dinges²,

Ropp

et al. 2007

Pathologe

View full text Add to dashboard Cite

Within the 5 years prior to diagnosis, no gynaecological cytological smear was found for 50% of the patients diagnosed with cervical cancer in the years 2000-2002. In the year 2002, a total of 53 patients were reported to have cervical cancer and 78 smears were reevaluated. Of all the smears primarily diagnosed as negative, 49% were found to be positive (> or =Pap III) after reevaluation and 92% of all smears "correctly" diagnosed as negative showed quality deficiencies. The interobserver variability (kappa-statistics) showed a moderate value when the primary screening results were compared with the reevaluation. The interobserver variability within the group of reevaluators was also moderate.

show abstract

Cervical Cytologic Smear False Negative Fraction

Cited by 4 publications

References 16 publications

Quality assurance in cervical screening of a high risk population: A study of 65,753 reviewed cases in Parana screening program, Brazil

Quality assurance in cervical screening of a high risk population: A study of 65,753 reviewed cases in Parana screening program, Brazil

Zervixkarzinome in Mecklenburg-Vorpommern

Reevaluation von Zervixabstrichen bei Zervixkarzinompatientinnen

Contact Info

Product

Resources

About